SWOG clinical trial number
CTSU/C10501
A Phase III intergroup CLL study of asymptomatic patients with untreated chronic lymphocytic leukemia randomized to early intervention versus observation with later treatment in the high risk genetic subset with IgVH unmutated disease
Closed
Phase
Abbreviated Title
CALGB - Phase III Early Intervention vs. Observation w/ Later Treatment for IgVH unmutated CLL
Activated
09/15/2008
Closed
01/05/2010
Participants
CTSU
Research committees
Leukemia
Treatment
Allopurinol
Fludarabine Phosphate
Rituximab
Eligibility Criteria Expand/Collapse
The Southwest Oncology Group has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.
Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org/) for more information and registration procedures.
Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org/) for more information and registration procedures.
Other Clinical Trials
SWOG Clinical Trial Number
S2504
A Randomized Phase III Study of PIRtobrutinib plus R-CHOP vs. R-CHOP for Patients with Previously UntreateD RIchter TrAnsforMation (RT) (pirAMID)
Research Committee(s)
Leukemia
Lymphoma
Activated
06/01/2026
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S1925
A Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL): EVOLVE CLL Study.
Research Committee(s)
Leukemia
Lymphoma
Symptom Management and Survivorship
Activated
12/14/2020
Accrual
80%
Open
Phase
SWOG Clinical Trial Number
CTSU/AALL1821
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old with First Relapse
Research Committee(s)
Leukemia
Activated
12/04/2020
Open